^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    AmoyDx® HANDLE HRR NGS Panel

    Company:
    Amoy Diagnostics
    Type:
    CE Marked
    Related tests:
    Details
    Evidence

    News

    1year
    Prevalence of HRR gene mutations in patients with metastatic prostate cancer (mPC): results from a single center in Mexico (EMUC 2023)
    70% received docetaxel, 84% novel antiandrogens, 28% cabazitaxel, 16% other treatments. Presence and type of alterations may vary within populations even in same regions. Further study is warranted.
    Clinical • BRCA Biomarker • Metastases
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • ATM (ATM serine/threonine kinase) • HRD (Homologous Recombination Deficiency) • CHEK2 (Checkpoint kinase 2)
    |
    BRCA2 mutation • BRCA1 mutation • ATM mutation
    |
    AmoyDx® HANDLE HRR NGS Panel
    |
    docetaxel • cabazitaxel
    almost2years
    Prevalence of HRR gene mutations in patients with metastatic castration-resistant prostate cancer: Germline results from the Latin-American observational study PROSPECT. (ASCO-GU 2023)
    The prevalence of germline HRR mutations found in this multinational Latin American population was lower than expected compared to previously reported rates ranging from 8% to 12% from other countries. Additionally, the most frequently mutated HRR genes differed from those from major trials including PROfound (NCT02987543). Clinical trial information: NCT04962880.
    Observational data • Clinical • BRCA Biomarker • Metastases
    |
    BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • CHEK2 (Checkpoint kinase 2) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • HOXB13 (Homeobox B13)
    |
    ATM mutation • CHEK2 mutation • BRIP1 mutation
    |
    AmoyDx® HANDLE HRR NGS Panel